Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen
hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for
the ideal oestrogen therapy

Jonathan Douxfils; Jean-Michel Foidart; Ulysse Gaspard; Guillaume Chatel; Mélanie Taziaux; Maud Jost; Céline Gérard; Laure Morimont

doi:10.5114/pm.2023.128815

eISSN: 2299-0038
ISSN: 1643-8876

Menopause Review/Przegląd Menopauzalny

Current issue Archive Online First About the journal Editorial board Editorial office Publisher Abstracting and indexing Subscription Contact Ethical standards and procedures Special Issues Instructions for authors Publication charge

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

2/2023
vol. 22

Send email

Copy url:

abstract:

Letter to the Editor

Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for the ideal oestrogen therapy

Jonathan Douxfils

¹

,

Jean-Michel Foidart

²

,

Ulysse Gaspard

²

,

Guillaume Chatel

³

,

Mélanie Taziaux

³

,

Maud Jost

³

,

Céline Gérard

³

,

Laure Morimont

¹

Department of Pharmacy, Namur Research for Life Sciences, Namur Thrombosis and Hemostasis Center, University of Namur, Namur, Belgium
Department of Gynecology, University of Liège, Liège, Belgium
Mithra Pharmaceuticals, Liège, Belgium

Menopause Rev 2023; 22(2): 117-119

DOI: https://doi.org/10.5114/pm.2023.128815

Online publish date: 2023/06/28

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Douxfils J, Foidart J, Gaspard U, et al. Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen
hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for
the ideal oestrogen therapy. Menopause Review/Przegląd Menopauzalny. 2023;22(2):117-119. doi:10.5114/pm.2023.128815.

APA

Douxfils, J., Foidart, J., Gaspard, U., Chatel, G., Taziaux, M.,  & Jost, M. et al. (2023). Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen
hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for
the ideal oestrogen therapy. Menopause Review/Przegląd Menopauzalny, 22(2), 117-119. https://doi.org/10.5114/pm.2023.128815

Chicago

Douxfils, Jonathan, Jean-Michel Foidart, Ulysse Gaspard, Guillaume Chatel, Mélanie Taziaux, Maud Jost,  and Céline Gérard et al. 2023. "Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen
hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for
the ideal oestrogen therapy". Menopause Review/Przegląd Menopauzalny 22 (2): 117-119. doi:10.5114/pm.2023.128815.

Harvard

Douxfils, J., Foidart, J., Gaspard, U., Chatel, G., Taziaux, M., Jost, M., Gérard, C.,  and Morimont, L. (2023). Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen
hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for
the ideal oestrogen therapy. Menopause Review/Przegląd Menopauzalny, 22(2), pp.117-119. https://doi.org/10.5114/pm.2023.128815

MLA

Douxfils, Jonathan et al. "Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen
hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for
the ideal oestrogen therapy." Menopause Review/Przegląd Menopauzalny, vol. 22, no. 2, 2023, pp. 117-119. doi:10.5114/pm.2023.128815.

Vancouver

Douxfils J, Foidart J, Gaspard U, Chatel G, Taziaux M, Jost M et al. Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen
hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for
the ideal oestrogen therapy. Menopause Review/Przegląd Menopauzalny. 2023;22(2):117-119. doi:10.5114/pm.2023.128815.

PlumX metrics:

Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for the ideal oestrogen therapy

Jonathan Douxfils 1 , Jean-Michel Foidart 2 , Ulysse Gaspard 2 , Guillaume Chatel 3 , Mélanie Taziaux 3 , Maud Jost 3 , Céline Gérard 3 , Laure Morimont 1

Jonathan Douxfils

¹

,

Jean-Michel Foidart

²

,

Ulysse Gaspard

²

,

Guillaume Chatel

³

,

Mélanie Taziaux

³

,

Maud Jost

³

,

Céline Gérard

³

,

Laure Morimont

¹